Published in Cancer Weekly, February 20th, 1995
Arun Srivastava, Indiana University School of Medicine, Indianapolis, noted that researchers recently have shown interest in AAV-based vectors. Unlike the more commonly used retroviral vectors, parvovirus-based vectors may become a useful alternative in gene therapy ("Parvovirus-Based Vectors for Human Gene Therapy," Blood Cells, 1994;20:531-538).
Srivastava noted that AAV, a parvovirus of human origin, is nonpathogenic, and site-specific integration...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.